Summit Therapeutics (NASDAQ: SMMT) is one of those stocks that have been quite explosive: The share price of the ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative dis ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

The closing of the merger is expected to occur as soon as practicable, subject to the satisfaction or waiver of the remaining customary closing conditions. Following the closing of the merger, the ...

Anti-VEGF not only inhibits angiogenesis but also ... which leads to enhanced efficacy of anti-PD-(L)1 inhibitors. Combining anti-PD-(L)1 antibodies with antiangiogenic agents was found to have ...

Detailed price information for Clearside Biomedi (CLSD-Q) from The Globe and Mail including charting and trades.

a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI ...